Everything Threat Times has reported about drug development: 3 stories, newest first. Part of our AI coverage.
OpenAI has acquired Orchestra Bio, a startup specializing in AI agents for drug development, with plans to incorporate the technology into its Rosalind life sciences platform.
OpenAI announces the acquisition of Orchestra Bio, aiming to integrate AI capabilities into biopharma research and accelerate drug development processes.
Denver startup Intero Biosystems is shipping mini human organs to pharmaceutical companies seeking alternatives to animal testing models.